Odds ratios of treatment response were well approximated from continuous rating scale scores for meta-analysis

Journal of Clinical Epidemiology

Volumn 68, Issue 7, 2015, Pages 740-751

  Meister, Ramona ^a   Von Wolff, Alessa ^a   Kriston, Levente ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Continuous end point; Depression; Dichotomous end point; Estimation method; Meta analysis; Odds ratio; Response rate; Standardized mean difference

Indexed keywords

AMFEBUTAMONE; AMISULPRIDE; AMITRIPTYLINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; IMIPRAMINE; LEVACECARNINE; MINAPRINE; MIRTAZAPINE; MOCLOBEMIDE; PAROXETINE; PLACEBO; REBOXETINE; RITANSERIN; SERTRALINE;

ARTICLE; COX AND SNELL METHOD; DEPRESSION; EFFECT SIZE; ERROR; FURUKAWA METHOD; HASSELBLAD AND HEDGES METHOD; HUMAN; KRAEMER AND KUPFER METHOD; META ANALYSIS (TOPIC); PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RISK; SCORING SYSTEM; SUISSA METHOD; THERAPY EFFECT; TREATMENT RESPONSE; CHRONIC DISEASE; COMPARATIVE STUDY; EVIDENCE BASED MEDICINE; FACTUAL DATABASE; META ANALYSIS; METHODOLOGY; PROCEDURES; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

CHRONIC DISEASE; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; DEPRESSION; EVIDENCE-BASED MEDICINE; HUMANS; META-ANALYSIS AS TOPIC; ODDS RATIO; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 84930570672     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2015.02.006     Document Type: Article

References (53)

1. J. Howick, I. Chalmers, P. Glasziou, T. Greenhalgh, C. Heneghan, and A. Liberati The oxford levels of evidence 2 2011 Oxford Centre for Evidence-Based Medicine Available at http://www.cebm.net/index.aspx?o=5653
2. J.P. Higgins, and S. Green Cochrane handbook for systematic reviews of interventions. Version 5.1.0 2011 The Cochrane Collaboration Available at http://www.cochrane-handbook.org Accessed March, 2011
3. J.B. Williams A structured interview guide for the Hamilton Depression Rating Scale Arch Gen Psychiatry 45 1988 742 747
4. A. Whitehead, A.J. Bailey, and D. Elbourne Combining summaries of binary outcomes with those of continuous outcomes in a meta-analysis J Biopharm Stat 9 1999 1 16
5. B. Da Costa, E. Nüesch, A. Rutjes, B. Johnston, S. Reichenbach, and S. Trelle Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study J Clin Epidemiol 66 2013 847 855
6. D. Simel, J. Easter, and G. Tomlinson Likelihood ratios, sensitivity, and specificity values can be back-calculated when the odds ratios are known J Clin Epidemiol 66 2013 458 460
7. A. Von Wolff, L.P. Hölzel, A. Westphal, M. Härter, and L. Kriston Combination of pharmacotherapy and psychotherapy in the treatment of chronic depression: a systematic review and meta-analysis BMC Psychiatry 12 2012 61
8. A. Von Wolff, L.P. Hölzel, A. Westphal, M. Härter, and L. Kriston Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: a systematic review and meta-analysis J Affect Disord 144 2013 7 15
9. L. Kriston, A. von Wolff, A. Westphal, L.P. Hölzel, and M. Härter Efficacy and acceptability of acute treatments for persistent depressive disorder: a network meta-analysis Depress Anxiety 31 2014 621 630
10. T.A. Furukawa, A. Cipriani, C. Barbui, P. Brambilla, and N. Watanabe Imputing response rates from means and standard deviations in meta-analyses Int Clin Psychopharmacol 20 2005 49 52
11. B.R. Da Costa, A.W.S. Rutjes, B.C. Johnston, S. Reichenbach, E. Nüesch, and T. Tonia Methods to convert continuous outcomes into odds ratios of treatment response and numbers needed to treat: meta-epidemiological study Int J Epidemiol 41 2012 1445 1459
12. J. Anzures-Cabrera, A. Sarpatwari, and J.P. Higgins Expressing findings from meta-analyses of continuous outcomes in terms of risks Stat Med 30 2011 2967 2985
13. K. Thorlund, S.D. Walter, B.C. Johnston, T.A. Furukawa, and G.H. Guyatt Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability Res Synth Meth 2 2011 188 203
14. P. Cuijpers, F. Smit, S.D. Hollon, and G. Andersson Continuous and dichotomous outcomes in studies of psychotherapy for adult depression: a meta-analytic comparison J Affect Disord 126 2010 349 357
15. M.T. Samara, L.M. Spineli, T.A. Furukawa, R.R. Engel, J.M. Davis, and G. Salanti Imputation of response rates from means and standard deviations in schizophrenia Schizophr Res 151 2013 209 214
16. T.A. Furukawa, and S. Leucht How to obtain NNT from Cohen's d: comparison of two methods PLoS One 6 2011 e19070
17. S. Chinn A simple method for converting an odds ratio to effect size for use in meta-analysis Stat Med 19 2000 3127 3131
18. V. Hasselblad, and L. Hedges Meta-analysis of screening and diagnostic tests Psychol Bull 117 1995 167 178
19. D.R. Cox, and E.J. Snell Analysis of binary data 1989 Chapman and Hall London
20. S. Suissa Binary methods for continuous outcomes: a parametric alternative J Clin Epidemiol 44 1991 241 248
21. H.C. Kraemer, and D.J. Kupfer Size of treatment effects and their importance to clinical research and practice Biol Psychiatry 59 2006 990 996
22. L. Kriston, A. von Wolff, and L. Hölzel Effectiveness of psychotherapeutic, pharmacological, and combined treatments for chronic depression: a systematic review (METACHRON) BMC Psychiatry 10 2010 95
23. A. Dechartres, D.G. Altman, L. Trinquart, I. Boutron, and P. Ravaud Association between analytic strategy and estimates of treatment outcomes in meta-analyses JAMA 312 2014 623 630
24. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0 2008 The Nordic Cochrane Centre, The Cochrane Collaboration Copenhagen
25. R Develoment Core Team R: A language and environment for statistical computing. Version 3.0.3 2013 R Foundation for Statistical Computing Vienna
26. V. Agosti, and K. Ocepek-Welikson The efficacy of imipramine and psychotherapy in early-onset chronic depression: a reanalysis of the National Institute of Mental Health Treatment of Depression Collaborative Research Program J Affect Disord 43 1997 181 186
27. I. Elkin, T. Shea, J. Watkins, S. Imber, S. Sotsky, and J. Collins National Institute of Mental Health Treatment of Depression Collaborative Research Program. General effectiveness of treatments Arch Gen Psychiatry 46 1989 971 983
28. M. Amore, and M.C. Jori Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study Int Clin Psychopharmacol 16 2001 317 324
29. H. Anisman, A. Ravindran, J. Griffiths, and Z. Merali Interleukin-1β production in dysthymia before and after pharmacotherapy Biol Psychiatry 46 1999 1649 1655
30. E. Baca, M. González de Chávez, M. García-Toro, F. Pérez-Arnau, and A. Porras-Chavarino Sertraline is more effective than imipramine in the treatment of non-melancholic depression: results from a multicentre, randomized study Prog Neuropsychopharmacol Biol Psychiatry 27 2003 493 500
31. S. Bellino, G. Barzega, F. Bogetto, G. Maina, S. Venturello, and L. Ravizza An open-label, randomized, prospective comparison of sertraline and amisulpride in the treatment of dysthymia in the elderly Curr Ther Res 58 1997 798 808
32. G. Bersani, F. Pozzi, S. Marini, A. Grispini, A. Pasini, and N. Ciani 5-HT 2 receptor antagonism in dysthymic disorder: a double-blind placebo-controlled study with ritanserin Acta Psychiatr Scand 83 1991 244 248
33. D.P. Devanand, M.S. Nobler, J. Cheng, N. Turret, G.H. Pelton, and S.P. Roose Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder Am J Geriatr Psychiatry 13 2005 59 68
34. A. Duarte, H. Mikkelsen, and A. Delini-Stula Moclobemide versus fluoxetine for double depression: a randomized double-blind study J Psychiatr Res 30 1996 453 458
35. D. Hellerstein, P. Yanowitch, J. Rosenthal, L. Samstag, M. Maurer, and K. Kasch A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia Am J Psychiatry 150 1993 1169 1175
36. D.J. Hellerstein, S.T. Batchelder, S. Hyler, B. Arnaout, C. Toba, and I. Benga Escitalopram versus placebo in the treatment of dysthymic disorder Int Clin Psychopharmacol 25 2010 143 148
37. D.J. Hellerstein, J.W. Stewart, P.J. McGrath, D.A. Deliyannides, S.T. Batchelder, and S.R. Black A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression J Clin Psychiatry 73 2012 984 991
38. C. Katona, E. Bercoff, E. Chiu, P. Tack, M. Versiani, and H. Woelk Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial J Affect Disord 55 1999 203 213
39. J. Kocsis, A. Frances, C. Voss, J. Mann, B. Mason, and J. Sweeney Imipramine treatment for chronic depression Arch Gen Psychiatry 45 1988 253 257
40. A. Ravindran, H. Anisman, Z. Merali, Y. Charbonneau, J. Telner, and R. Bialik Treatment of primary dysthymia with group cognitive therapy and pharmacotherapy: clinical symptoms and functional impairments Am J Psychiatry 156 1999 1608 1617
41. A.V. Ravindran, C. Cameron, R. Bhatla, L.N. Ravindran, and T.L. Da Silva Paroxetine in the treatment of dysthymic disorder without co-morbidities: a double-blind, placebo-controlled, flexible-dose study Asian J Psychiatr 6 2013 157 161
42. L. Ravizza Amisulpride in medium-term treatment of dysthymia: a six-month, double-blind safety study versus amitriptyline. AMILONG investigators J Psychopharmacol 13 1999 248 254
43. P. Rocca, V. Fonzo, L. Ravizza, G. Rocca, M. Scotta, and E. Zanalda A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder J Affect Disord 70 2002 313 317
44. P. Rocca, L. Marchiaro, R. Rasetti, E. Rivoira, and F. Bogetto A comparison of paroxetine versus paroxetine plus amisulpride in the treatment of dysthymic disorder: efficacy and psychosocial outcomes Psychiatry Res 112 2002 145 152
45. A. Rush, L. Koran, M. Keller, J. Markowitz, W. Harrison, and R. Miceli The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies J Clin Psychiatry 59 1998 589 597
46. M. Keller, J. Gelenberg, R. Hirschfeld, A. Rush, M. Thase, and J. Kocsis The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine J Clin Psychiatry 59 1998 598 607
47. A. Rush, M.H. Trivedi, J.W. Stewart, A. Nierenberg, M. Fava, and B.T. Kurian Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study Am J Psychiatry 168 2011 689 701
48. E. Salzmann, and J. Robin Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders Neuropsychobiology 31 1995 68 75
49. E. Smeraldi Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind, comparative study J Affect Disord 48 1998 47 56
50. M. Thase, M. Fava, U. Halbreich, J. Kocsis, L. Koran, and J. Davidson A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia Arch Gen Psychiatry 53 1996 777 784
51. J.M. Vanelle, D. Attar-Levy, M.F. Poirier, M. Bouhassira, P. Blin, and J.P. Olié Controlled efficacy study of fluoxetine in dysthymia Br J Psychiatry 170 1997 345 350
52. M. Versiani, R. Amrein, and M. Stabl Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group Int Clin Psychopharmacol 12 1997 183 193
53. R. Zanardi, and E. Smeraldi A double-blind, randomised, controlled clinical trial of acetyl-l-carnitine vs. amisulpride in the treatment of dysthymia Eur Neuropsychopharmacol 16 2006 281 287